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Abstract
Background: Restrictions on face-to-face contact, due to COVID-19, led to a rapid adoption of technology to 
remotely deliver cardiac rehabilitation (CR). Some technologies, including Active+me, were used without knowing 
their benefts. We assessed changes in patient activation measure (PAM) in patients participating in routine CR, using 
Active+me. We also investigated changes in PAM among low, moderate, and high risk patients, changes in cardiovas-
cular risk factors, and explored patient and healthcare professional experiences of using Active+me. 
Methods: Patients received standard CR education and an exercise prescription. Active+me was used to monitor 
patient health, progress towards goals, and provide additional lifestyle support. Patients accessed Active+me through 
a smart-device application which synchronised to telemetry enabled scales, blood pressure monitors, pulse oxime-
ter, and activity trackers. Changes in PAM score following CR were calculated. Sub-group analysis was conducted on 
patients at high, moderate, and low risk of exercise induced cardiovascular events. Qualitative interviews explored the 
acceptability of Active+me. 
Results: Forty-six patients were recruited (Age: 60.4±10.9years; BMI: 27.9±5.0 kg.m2; 78.3% male). PAM scores 
increased from 65.5 (range: 51.0 to 100.0) to 70.2 (range: 40.7 to 100.0; P =0.039). PAM scores of high risk patients 
increased from 61.9 (range: 53.0 to 91.0) to 75.0 (range: 58.1 to 100.0; P =0.044). The PAM scores of moderate and low 
risk patients did not change. Resting systolic blood pressure decreased from 125mmHg (95% CI: 120 to 130mmHg) 
to 119mmHg (95% CI: 115 to 122mmHg; P =0.023) and waist circumference measurements decreased from 92.8cm 
(95% CI: 82.6 to 102.9cm) to 85.3cm (95% CI 79.1 to 96.2cm; P =0.026). Self-reported physical activity levels increased 
from 1557.5 MET-minutes (range: 245.0 to 5355.0 MET-minutes) to 3363.2 MET-minutes (range: 105.0 to 12,360.0 MET-
minutes; P <0.001). Active+me was acceptable to patients and healthcare professionals. 
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Conclusion: Participation in standard CR, with Active+me, is associated with increased patient skill, knowledge, and 
confdence to manage their condition. Active+me may be an appropriate platform to support CR delivery when 
patients cannot be seen face-to-face. 
Trial registration: As this was not a clinical trial, the study was not registered in a trial registry. 
Keywords: Cardiac rehabilitation, Patient activation, Self-efcacy, Tele-health, COVID-19 
Introduction 
In 2020, a highly contagious virus, known as COVID-
19 [1], resulted in international governments restricting 
face-to-face contact [2]. Tis led to the suspension of 
‘non-essential’ healthcare services, including half of car-
diac rehabilitation (CR) services in the United Kingdom 
[3]. However, CR programmes that were not suspended 
adapted rapidly. Tree-quarters (77.6%) of programmes 
introduced digital platforms to deliver CR for the frst 
time between 11th March 2020 [3], when COVID-19 
was declared a pandemic by the World Health Organisa-
tion [4], and 20th June 2020 [3]. However, the beneft of 
some digital platforms on patient outcomes are unknown 
[3]. Furthermore, evidence suggested that some patient 
groups, including those at high risk of exercise-induced 
cardiovascular events [5], were not being ofered exer-
cise-based CR using technology [3]. Tere is as a need to 
identify which platforms adopted during the COVID-19 
pandemic are efective and safe, particularly for high risk 
patients.
In March 2020, Addenbrooke’s Hospital (Cambridge 
University Hospitals NHS Foundation Trust, UK) intro-
duced a customisable telemetry system called Active+me 
(Aseptika Ltd, St Ives, UK). Active+me was accessed by 
patients through a tablet or smart phone. Healthcare 
professionals controlled the content that was available 
to patients, and communicated with patients, through a 
PC terminal. Active+me was used to monitor and pro-
vide additional support to patients participating in a 
routine, eight-week, comprehensive CR programme [6]
that had transitioned to remote service delivery due to 
the COVID-19 pandemic. Active+me was designed to 
increase patient activation, a term used to describe the 
level of knowledge, skill, and confdence a patient has to 
self-management their condition [7]. Patient activation 
can be measured using the patient activation measure 
(PAM) questionnaire [8].
Patient activation measure scores are associated with 
health outcomes. Patients with chronic heart failure 
(CHF) who are admitted to hospital are 10% more likely 
to be discharged home, rather than to a ‘skilled nursing 
facility’, with each 1-point increase in PAM score (odds 
ratio [OR] 1.08; 95% CI: 1.03 to 1.14, P <0.001) [9]. Con-
versely, 30day mortality rates increase by 10% with each 
1-point decrease in PAM score, in patients with CHF 
(hazard ratio 1.09, 95% CI 1.03 to 1.16, P =0.006) [9].
Similarly, patients with coronary heart disease (CHD)
with the lowest levels of activation (level 1) are more 
likely to experience clinically signifcant declines in men-
tal health (OR 1.95; 95% CI: 1.05 to 3.62), and disease 
specifc health-related quality of life (OR 2.18; 95% CI: 
1.17 to 4.05; P <0.05), 1 month after hospital discharge 
[10]. Tus, increasing patient activation may reduce 
healthcare costs, improve patient health-related quality 
of life, and reduce the risk of death, in the short-term. 
Te primary aim of this cohort study was to determine 
whether participating in CR, with Active+me, led to an 
increase in PAM score. To help overcome the hesitance 
of services providing remote CR to high risk patients 
[3], we also explored changes in PAM scores in patients 
categorised at high, moderate, and low risk of exercise-
induced cardiovascular events [5]. Finally, we investi-
gated patient and healthcare professionals’ experiences of 
using Active+me. 
Methods 
Participants & consent 
Ethical approval for the evaluation was obtained 
from Shefeld Hallam University Ethics Committee 
(ER26525336). Te evaluation was also approved by 
Addenbrooke’s Hospital (ID 3224; Ref no. PRN9224). 
Study procedures conform to the 1975 Declaration of 
Helsinki and is subsequent revisions. Informed con-
sent was obtained by a member of the patient’s immedi-
ate healthcare team prior to enrolling patients on to the 
service evaluation. Consent was recorded in the patient 
healthcare record. Written informed consent was also 
obtained for interviews conducted with patients and 
healthcare professionals. Reporting of fndings adhere to 
STROBE guidelines (Appendix 1) [11].
As this was a service evaluation, no formal sampling 
strategy was used. Patients referred for routine, 8 week, 
Phase III CR were sequentially invited to participate 
in CR with Active+me between the 6th April 2020 and 
27th July 2020. Patients who were>18years of age with 
a recent diagnosis of atherosclerosis, angina, myocardial 
infarction (MI), CHF, or had undergone coronary artery 
bypass graft (CABG) surgery, elective percutaneous cor-
onary intervention (PCI), or valve surgery, were eligible 
for recruitment. Because this was a routine healthcare 







service, the only exclusion criterion was an absolute con-
traindication to exercise training [5]. Patients underwent 
an initial, remote, holistic assessment by a CR health-
care professional approximately 1 week before com-
mencing CR. Assessments were used to assess lifestyle 
and medical risk factors [6], and formulate a treatment 
plan including exercise training. Healthcare profession-
als scored patients as either high, moderate, or low risk 
of exercise-induced cardiovascular events using estab-
lished criteria [5]. A follow-up assessment was conducted 
approximately 1 week after completing CR. Patients 
were free to decline Active+me. Patients who declined 
Active+me received exercise and lifestyle advice over the 
telephone a written exercise programme was also pro-
vided at the discretion of the healthcare professional, 
when appropriate. 
Active+me 
Active+me is a medically certifed (CE marked Class I) 
telemetry device (ISO 13485:2016) and has a fully cus-
tomisable suite of lifestyle education (e.g. weight man-
agement) and behaviour change support, live exercise 
classes, physical activity, health monitoring tools, and 
medication diaries. Te platform was designed using 
the principles of behaviour change described by Abra-
ham & Michie [12]. However, a healthcare professional 
can decide what resources to provide to patients and 
when they are provided. Tis includes which behav-
iour change techniques to use. Patients were provided 
with Active+me, via post, when they enrolled on to CR. 
An instruction manual and DVD explaining how to set 
up the devices were provided. Patients using Active+me 
were also provided with a physical activity tracker, auto-
mated blood pressure monitor with heart rate detec-
tion, pulse oximeter, and body mass scales. All devices 
were linked using Bluetooth to a smart device through 
an application downloaded from the Android (Mountain 
View, California, USA), Kindle Fire (Seattle, Washington, 
United States), or Apple (Cupertino, California, USA) 
app stores. Healthcare professionals communicated with 
patients throughout the programme, monitored patient 
progress towards achieving goals, and patient engage-
ment with CR using data transmitted from their acces-
sory devices to a personal computer terminal. Healthcare 
professionals reviewed patient progress at least once per 
week and communicated with patients at least once every 
3 weeks. Technical support was provided throughout the 
CR programme by Aseptika Ltd. 
Patient activation 
Active+me is designed to increase patient activation, a 
term describing the knowledge, skill, and confdence a 
patient has to manage their health [7]. Patient activation 
is measured using the 13-item PAM short-form ques-
tionnaire [8], scored on a theoretical scale from 0 to 100. 
Scores are categorised into one of four patient activation 
levels, where 1 and 4 denote the lowest and highest level 
of patient activation, respectively [7, 8]. Level 1 (Scores 
of 0.0 to 47.0) highlights disengagement and disbelief 
about the patient’s own role in self-management. Level 
2 (scores of 47.1 to 55.1) indicates an increasing aware-
ness, confdence, and knowledge in self-management 
tasks, however large gaps in their ability to manage their 
own health remain. Level 3 (scores of 55.2 to 72.4) shows 
a patient’s readiness and taking action and level 4 (scores 
of and 72.5 to 100) suggests that patients have adopted 
new behaviours and maintaining these is a priority [13].
Change in PAM score (0–100) was the primary outcome 
measure for this study. Patients completed a PAM ques-
tionnaire when they enrolled on the Active+me pro-
gramme and at the end of the eight-week CR programme. 
Anthropometric measurements 
Face-to-face assessments were suspended due to 
COVID-19 restrictions [2] so height (cm) and waist cir-
cumference was measured by patients, at home, using an 
infexible tape measure. Patients were instructed to take 
their waist circumference measurements at the height of 
the navel. Resting blood pressure and heart rate measure-
ments were measured using the automated blood pres-
sure machine provided. Patients were asked to sit for at 
least 5 min before taking their resting blood pressure and 
heart rate measurements. Body mass was measured using 
the scales provided. Body mass was divided by height 
squared, and expressed as body mass index (BMI; kg.m2). 
Physical activity measurements 
Physical activity was measured using the wrist-worn 
accelerometer which recorded daily minutes of par-
ticipated physical activity and total daily step count. 
Te activity tracker did not measure exercise intensity 
so patients also completed a Total Activity Measure 2 
(TAM2) questionnaire [14] at the start and end of the CR 
programme. Te TAM2 questionnaire has been validated 
in patients with heart disease [14] and can be used to 
estimate how many Metabolic Equivalent of Task-Min-
utes (MET-minutes) of physical activity a patient com-
pletes each week. MET-minutes provide an estimated 
composite score of physical activity dose characteristics, 
including intensity, duration, and frequency [14]. 
Psychosocial health questionnaires 
At the start and end of the CR programme, health care 
professionals provided each patient with a Patient Health 
Questionnaire (PHQ) [15], Generalised Anxiety Disor-
der (GAD) Questionnaire [16], and the Work and Social 
















Adjustment Scale (WAS) [17], to measure changes in 
depression [15] and anxiety [16] symptoms as well as 
health-related quality of life [17]. Tese were dispatched 
and returned using postal services. 
Adverse events 
Adverse events were reported to assess the beneft and 
risk profle of the intervention. Serious adverse events 
were defned as any event or reaction that resulted in 
death, life-threatening illness, hospital admission or pro-
longation of existing hospitalisation, persistent or sig-
nifcant disability or incapacity [18]. Adverse events were 
defned as any untoward medical event that occurred 
during activities required for the study [18], irrespec-
tive of whether they were thought to be related to the 
intervention. 
Interviews 
Patient interviews lasted up to 45min and were con-
ducted after completion of CR by a single member of the 
research team (KC). A representative sample of patients 
were recruited using heterogeneous purposive sam-
pling; cardiac diagnosis, age, sex, ethnicity, and follow-up 
PAM score were considered. Recruitment for interviews 
stopped when data saturation was met [19]. Data satura-
tion was reached when no new information was attained. 
A member of the research team contacted patients to 
explain the purpose of the interviews and obtain addi-
tional informed consent. Interviews were conducted 
using video conferencing software, supported by a topic 
guide focusing on patient’s experiences of the Active+me 
programme (Table  1). At study completion, healthcare 
professionals involved with the delivery of Active+me 
were also interviewed for up to 60min, supported by a 
topic guide (Table 1).
Interviews were analysed using thematic analysis 
[20]. Audio recordings were transcribed verbatim by an 
external transcription company for analysis. Transcripts 
were read, and re-read, to develop familiarity with the 
data. Te transcripts were uploaded to NVivo version 
12 (QSR International Pty Ltd., 2019). Sections of raw 
data that were of interest were highlighted and assigned 
an initial code. Responses were coded inductively. Once 
transcripts had been coded the raw data extracts for 
each theme were re-read, merged, refned, or removed, 
as appropriate. GF led the interpretation of the data and 
KC shared refective notes from each of the interviews to 
add richness to the themes identifed [21]. Concepts were 
allocated to higher and lower order themes. 
Sample size 
Previous data suggests that CR, delivered using telem-
etry, leads to a 4.8 unit, within group, increase in PAM 
scores (95% CI: 1.6 to 8) [22]. We converted the 95% CI 
in to standard deviation (±) using the equation published 
by the Cochrane Collaboration [23]. Te mean change 
in PAM was 4.8±6.6. Tese data were used in a sample 
size calculation, performed using G*Power 3.1 [24]. Te 
signifcance threshold was set at P =0.05 and the power 
was set to 99%. Te required sample size was 38. Based 
on previous data from our group [25] we estimated that 
there would be up to 20% attrition. Tus, the sample size 
was set at n =46 participants. 
Statistical analysis 
Statistical analysis was conducted using SPSS version 
24 (IBM, New York, NY, USA). Normality was assessed 
visually and by using the Shapiro-Wilk test. Categori-
cal data are presented as frequency and percentages. 
Continuous normally distributed data are presented as 
mean with 95% confdence intervals. Non-normally dis-
tributed continuous data are presented as median with 
minimum and maximum values. Where missing data 
or participants were lost to follow-up the last observa-
tion was carried forward. A per-protocol analysis was 
also conducted on the primary outcome measure (PAM). 
Planned sub-group analysis was conducted on patients at 
high, moderate, and low risk of exercise-induced cardio-
vascular events, as defned by established guidelines [5].
To avoid type II error, sub-group analysis was only con-
ducted on the primary outcome measure (PAM score). 
For parametric data, group diferences were assessed 
using a One-Way ANOVA. A Kruskal-Wallace test was 
used for non-parametric data. Diferences in continuous, 
normally distributed, paired data were assessed using 
paired sample t-tests. A Wilcoxon signed-rank test was 
Table 1 Active+me evaluation topics for patients and healthcare professionals 
Patients Healthcare professionals
 • Recruitment and set up process
 • Experience of Active+me
 • Active+me resources
 • Usage of Active+me
 • Perceived efectiveness
 • Self-efcacy and Active+me
 • Health and behaviour change optimism 
• Attitude towards Active+me for patients 
• Impact of Active+me on clinical practice 
• Impact of Active+me on patients 
• Unintended consequences 




















used to assess diferences non-parametric paired data. A 
Chi-squared test was used to assess diferences between 
categorical variables. Where cells had an expected count 
<5, Fishers Exact Test was used. Signifcance was set at 
P <0.05. Baseline values were not used as covariates in 
any analysis. Efect sizes for ANOVA, and Wilcoxon 
signed rank tests, were calculated as η2, where 0.01, 0.06, 
and 0.140 denoted small, moderate, and large efect sizes, 
respectively [26]. Efect sizes for t-tests were calculated 
using Cohen’s D formula [27]. Efect sizes for Small, 
medium, and large efect sizes for Cohens were 0.2, 0.5, 
and 0.8, respectively [27]. 
Results 
Patient characteristics are shown in Table  2. Te num-
ber of complete responses to each outcome is shown in 
Appendix 2. Tere were 154 patients referred for CR. 
Forty-six (29.9%) patients were given Active+me and 
Table 2 Patient characteristics (mean; 95% confdence intervals) 
Characteristic All High Risk Moderate Risk Low Risk P-Value Efect Size 
Number of participant 46 (78.3) 10 (60.0) 13 (76.9) 23 (87.0) 0.224 – 
(% male) 
Age (years) 60.4 (57.1 to 63.6) 64.0 (56.4 to 71.6) 62.4 (55.1 to 69.7) 57.7 (53.3 to 62.0) 0.232 0.066 
Median Baseline PAM 65.5 (51.0 to 100) 61.9 (51.0 to 91.0) 58.1 (51.0 to 85.0) 65.5 (51.0 to 100) 0.180 0.261 
Scores (Range)✝ 
Daily Steps 8312.6 (7314.3 to 5482.3 (3666.6 to 7935.9 (5989.9 to 9882.0) 10,028.0 (8450.0 to 0.002* 0.286 
9571.8) 7298.1)a 11,611.0)a 
Daily Physical Activity 94.7 (81.1 to 109.8) 62.4 (42.1 to 82.7)a 94.1 (69.2 to 119.0) 111.0 (88.6 to 133.4)a 0.020* 0.196 
Duration (Minutes) 
Systolic Blood Pressure 125 (120 to 130) 129 (115 to 143) 115 (103 to 127) 128 (122 to 133) 0.059 0.135 
(mmHg) 
Diastolic Blood Pressure 75 (71 to 79) 73 (62 to 84) 69 (61 to 77) 75 (71 to 79) 0.120 0.103 
(mmHg) 
Resting Heart Rate 62 (44 to 93) 62 (44 to 93) 64 (47 to 83) 62 (44 to 93) 0.358 0.066 
(bpm) ✝ 
Body Mass Index 
(kg.m−2) 
27.9 (26.4 to 29.5) 30.6 (25.9 to 35.4) 25.6 (23.1 to 28.0) 28.0 (26.1 to 29.8) 0.060 0.131 
Waist Circumference 92.8 (82.6 to 102.9) 98.9 (83.1 to 114.7) 99.1 (88.4 to 109.8) 96.3 (84.1104.9) 0.926 0.008 
(cm) 
Ethnicity 
White British (%) 27 (80.4) 9 (90.0) 10 (76.9) 18 (78.3) 0.534 – 
Any other White 3 (6.5) 0 (0.0) 1 (7.7) 2 (8.7) 0.534 – 
background (%) 
Black Caribbean (%) 1 (2.2) 0 (0.0) 0 (0.0) 1 (4.3) 
Indian (%) 1 (2.2) 1(10.0) 0 (0.0) 0 (0.0) 
Any other Asian Back- 1 (2.2) 0 (0.0) 1 (7.7) 0 (0.0) 
ground (%) 
Not reported (%) 3 (6.5) 0 (0.0) 1 (7.7) 2 (8.7) 
Primary Reason for Referral 
Myocardial infarction 25 (54.3) 6 (60.0) 4 (30.8) 15 (65.2) 0.016* 
(%) 
Elective Percutaneous 10 (21.7) 1 (10.0) 6 (46.2) 3 (13.0) – 
coronary intervention 
(%) 
Chronic heart failure 3 (6.5) 3 (30.0) 0 (0.0) 0 (0.0) 
(%) 
Coronary artery 4 (8.7) 0 (0.0) 2 (15.4) 2 (8.7) 
bypass graft (%) 
Atherosclerosis (%) 2 (4.3) 0 (0.0) 0 (0.0) 2 (8.7) 
Arrhythmia (%) 1 (2.2) 0 (0.0) 1 (7.7) 0 (0.0) 
Valve surgery (%) 1 (2.2) 0 (0.0) 0 (0.0) 1 (4.3) 
PAM Patient Activation Measure 
✝ =Non-Parametric Analysis; * signifcant diference; a= signifcant diference between high risk and low risk patients 
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were included in the evaluation (Age: 60.4: 95% CI 57.1 
to 63.6years: BMI 27.9: 95% CI 26.4 to 29.5kg.m−2; 78.3% 
male). Reasons for patients not using Active+me included 
lacking the required smart device or internet connection, 
patients believing they already had tech similar technol-
ogy such as blood pressure monitors and activity track-
ers, patients not being interested in using Active+me, and 
language barriers. In some instances, clinicians declined 
to ofer Active+me to some patient because they felt it 
was not suitable for them. Te number of patients citing 
each reason for declining was not documented, nor was 
the average time to follow-up.
Most patients included for analysis were White Brit-
ish (n= 37; 80.4%) and referred following a MI (n= 25; 
54.3%). Half (n= 23; 50.0%) were classifed as ‘low risk’. 
Te low risk group had the largest proportion of patients 
with a PCI. Te high risk group had the largest propor-
tion of patients with CHF, or CABG. Tree patients were 
lost to follow-up (6.6%), of which, two (4.4%) discontin-
ued Active+me and one (2.2%) was discharged from CR 
early because the team were unable to make contact with 
them. Patients in the low risk group completed more 
daily steps (P =0.002) and accumulated more minutes of 
daily physical activity at baseline (P =0.020), compared 
to patients in the high risk group (Table 2). Tere were no 
adverse events during the evaluation.
Most patients were categorised as PAM level 3 
(50.0%) or 4 (30.4%) at baseline (Table  3). Patient PAM 
scores (Fig.  1) increased from 65.5 at baseline (range: 
51.0 to 100.0) to 70.2 after CR (40.7 to 100.0; P =0.039; 
η2 =0.101). Carrying the last observed PAM score for-
ward did not change this. Twenty-seven (n= 23; 53.4%)
patients had higher PAM scores after using Active+me. 
Four (n= 4; 9.3%) and 16 (37.2%) patients had no change 
in PAM scores or lower PAM scores after CR, respec-
tively (Fig.  2). Sub-group analysis showed that PAM 
scores in high risk patients (n= 10) increased from 
61.9 (range: 53.0 to 91.0) to 75.0 (range: 58.1 to 100.0; 
P =0.044; η2 =0.452). Te PAM scores of patients in 
moderate (baseline 58.1; 95% CI 51.0 to 100.0; after CR 
65.5; 95% CI 47.0 to 100.0; P =0.441; η2 =0.066) and low
risk groups did not change (baseline 66.7; 95% CI 51.0 
to 100; after CR 70.2 95% CI 40.7 to 100.0; P =0.522; 
η2 =0.020; Fig.  1). Te proportion of patients report-
ing an increase in PAM scores was largest in high risk 
patients (n= 7; 70%), followed by moderate (n= 6; 
54.5%) and low risk patients (n= 6; 45.4%; Fig. 2). Tere 
were no changes in PAM levels (1 to 4) overall, or within 
the diferent risk groups (P =0.107). 
Physical activity status and cardiometabolic risk factors 
Table  3 shows changes in physical activity and cardio-
metabolic risk factors. Te total duration of physical 
activity, measured using the physical activity tracker, did 
not change (mean change: 7.0min; 95% CI −6.4 to 20.5; 
P =0.296; d =0.100). However, self-reported weekly 
physical activity, estimated using the TAM2 question-
naire, increased by 1422.0 MET-minutes (range: −2495.0 
Table 3 Changes in outcome measures with Active+me (mean; 95% Confdence Intervals) 
Variable Baseline Follow-up P-Value Efect Size 
PAM Scores✝ 65.5 (51.0 to 100.0) 70.2 (40.7 to 100.0) 0.039* 0.101 
Patients with PAM Level 1 (%) 0 (0.0) 2 (4.3) 0.107 – 
Patients with PAM Level 2 (%) 6 (13.0) 4 (8.7) 
Patients with PAM Level 3 (%) 23 (50.0) 20 (43.5) 
Patients with PAM Level 4 (%) 14 (30.4) 17 (37.9) 
Daily Steps 8312 (7314 to 9571) 8484 (7020 to 9814) 0.734 0.045 
Daily Physical Activity Duration (Minutes) 94.7 (81.1 to 109.8) 101.7 (82.0 to 119.0) 0.296 0.100 
Body Mass Index (kg.m2) 27.9 (26.4 to 29.5) 27.7 (26.1 to 29.3) 0.126 0.067 
Resting Systolic Blood Pressure (mmHg) 125 (120 to 130) 119 (115 to 122) 0.023* 0.445 
Resting Diastolic Blood Pressure (mmHg) 75 (71 to 79) 72 (69 to 75) 0.184 0.234 
Resting Heart Rate✝ (bpm) 62 (44 to 93) 64 (46 to 87) 0.149 0.053 
Waist circumference (cm) 92.8 (82.6 to 102.9) 85.3 (79.1 to 96.2) 0.026* 0.506 
PHQ Questionnaire✝ 4.0 (0.0 to 23.0) 2.0 (0.0 to 19.0) 0.619 0.016 
GAD Questionnaire✝ 3.0 (0.0 to 21.0) 1.5 (0.0 to 14.0) 0.693 0.010 
WSA Scale Score✝ 4.0 (0.0 to 24.0) 1.0 (0.0 to 23.0) 0.906 0.001 
TAM2 Score✝ (MET-minutes per week) 1557.5 (245.0 to 5355.0) 3363.2 (105.0 to 12,360.0) <0.001* 0.419 
PAM Patient Activation Measure, PHQ Patient Health Questionnaire, General Anxiety Disorder, WSAWork and Social Adjustment, TAM2 Total Activity Measurement, 
MET Metabolic Equivalents 
✝=Non-Parametric Analysis; * signifcant diference 
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Fig. 1 Changes in patient activation measures scores among all patients (left), high risk patients (second from left), moderate risk patients (second 
from right), and low risk patients (right). *signifcant diference 
Fig. 2 Change in patient activation measure scores in low (green bars), moderate (orange bars), and high risk patients (red bars) 
to 9840.0 (P <0.001; η2 =0.419). More patients reported 
participating in 150min of moderate intensity physi-
cal activity per week at follow-up (n= 30; 69.8%) than 
baseline (n= 14; 31.0%), but this was not signifcant 
(P =0.147). Two patients participated in more than 
75min of vigorous physical activity at baseline (4.3%), 
and follow up (4.7%). Systolic blood pressure was lower 
at follow-up, compared to baseline (P =0.023; d =445),
but diastolic blood pressure did not change (P =0.184; 
d = 0.053). Waist circumference measurements were also 
smaller at follow-up, compared to baseline (P =0.026; 
d =0.506) but BMI did not change (P =0.126). However, 
there was a moderate efect size for lower body mass 
(η2 =0.067). Carrying the last observation forward did 
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not change the signifcance of the results. However, the 
change in waist circumference was smaller to −2.5cm 
(95% CI −0.2 to −4.8cm; P =0.033; d=0.163). 
Psychosocial questionnaires 
Te number of patients returning baseline and follow-up 
psychosocial questionnaires was small (n =17; Appen-
dix 2). Tere were no changes in any psychosocial meas-
urements, measured using questionnaires (all P >0.05; 
Table 3). 
Qualitative results 
Nine males and four females were interviewed (total 
n= 13; median age: 62.0years; range 46 to 79years). 
Eleven (84.6%) were White British, one was Asian (7.7%), 
and one Black Caribbean (7.7%). Interviews were con-
ducted with three CR Exercise Professionals. Tree 
higher-order themes were identifed (i) Facilitators of 
Active+me participation and adherence (ii) Barriers of 
Active+me participation and adherence (iii) Level of 
engagement with Active+me components. Further expla-
nation of the themes, and additional quotes, are shown in 
Appendix 3. 
Theme 1: Facilitators of Active+me participation 
and adherence 
Subtheme 1.1: Perceived usefulness of Active+me Patients 
and professionals believed Active+me participation was 
important during the COVID-19 pandemic because face-
to-face CR was suspended. Te healthcare professionals 
recognised the importance of the programme, and con-
sidered this an opportunity to build good communication 
with patients during this time, whilst ofering confdence 
that patients are ‘safe’ whilst exercising independently at 
home. 
“…It allowed us to get a lot more information on 
patients that we might not have got during COVID-
19 period”. (Healthcare professional 3) 
Subtheme 1.2: Programme benefts All patients dis-
cussed at least one beneft of participating and described 
an improvement in health-related confdence, physical 
activity levels, ability to manage their health, and/or psy-
chological wellbeing. Ten patients (76.9%) said their abil-
ity to manage their health had improved since participat-
ing in Active+me. Patients who discussed more benefts 
of attending the programme had larger increases in PAM 
scores. 
“I am a lot more aware of my health issues… I 
became a lot more involved in trying to change that 
for the better, rather than for the worse”. (Female, 47 
years) 
Subtheme 1.3: Self-motivation Goal setting, self-moni-
toring and belief in capability (self-efcacy) were all dis-
cussed as factors which infuenced participation. Patients 
considered a level of self-motivation was required in 
order to ‘get the most out of the programme’, predomi-
nantly because the programme was carried out indepen-
dently in their own home. 
“…II do my 10,000 steps and I haven’t missed a day, 
since I got it, every single day at the moment I’ve 
done the 10,000+ steps”. (Male, 71 years) 
Theme 2: Barriers to Active+me participation and adherence 
Subtheme 2.1: Perceived health status Nine out of the 13 
patients (69.2%) who engaged with the Active+me pro-
gramme discussed other chronic health conditions which 
impacted some patients’ ability, and perceived capability, 
to participate with some components of the programme. 
Tese included musculoskeletal conditions, strokes, anxi-
ety, and depression. Tose with co-morbidities were a 
mixture of low, moderate and ‘high risk’ patients. Not 
all patients who had co-morbidities were categorised as 
‘high risk’. Patients who had a co-morbidity were more 
likely to voice their apprehension or inability to engage 
with certain aspects of the programme and considered 
themselves less capable in the exercise component. 
“…I had other things that were other issues, particu-
larly this leg problem…which nobody can solve, it 
ruined my experience to a certain extent. It stopped 
me being able to get the full use out of it”. (Male 79 
years) 
Teme 2.2: Increased burden Even though Active+me 
was designed to provide fexibility in the scheduling of 
each of the programme components, including exer-
cise and physical activity, some patients had family or 
work commitments and perceived this as a barrier to 
participation. 
“Presently I am caring for my husband who has 
slight dementia and with the Type 1 diabetes that I 
have, life gets a bit tricky”. (Female, 67 years) 











Health care professionals considered time and other 
work commitments as a barrier to engaging with 
Active+me. Tere was a perception that Active+me 
needed to be better integrated into the processes of usual 
CR. However, over the project duration, the processes 
and procedures were streamlined to create better ways of 
working. 
“…it was at times quite time consuming for clini-
cians…it did take up quite a bit of time with review-
ing data in certain patients that needed more sup-
port. As the months went by, we learnt the best way 
of doing things and processes evolved and got bet-
ter and better to make it work for both us and the 
patients”. (Healthcare professional 2) 
Theme 3: Level of engagement with active+me programme 
components 
Subtheme 3.1: Self-monitoring components and health-
care professional support All 13 patients engaged with 
at least one element of Active+me. Te most utilised 
components were the physical activity tracker, the blood 
pressure monitor and scales. Ten (76.9%) of 13 patients 
engaged with the physical activity or step tracking com-
ponent, however, three (23.1%) patients lacked conf-
dence in their ability to complete the exercise compo-
nents believing that exercise would have a negative efect 
on their health. Proportionately, high and medium risk 
patients were more likely to discuss feeling disengaged 
when they used the smart device application due to the 
perceived level of ‘competition’ with other patients. 
“It made me feel bad… I couldn’t relate to people 
walking 10,000 steps in a day”. (Male, 79 years) 
A ‘one size fts all approach’ was not considered 
appropriate. Instead, a personalised approach was rec-
ommended by health care professionals and patients. 
Providing self-monitoring equipment and contact time 
support according to patient need. 
“I’d be maybe personalising a little bit more to each 
patient… so defnitely look at that side of things as to 
who gets what and what they need to be reviewing”. 
(Heath care professional 2) 
All interview patients discussed the importance of 
having a healthcare professional who was aligned with 
the programme to advise on health statistics, techni-
cal support and safety. Health care professional expe-
rience, knowledge of condition and reassurance were 
also viewed as especially important to patients. Health-
care professional support was considered valuable for 
monitoring patients, ofering reassurance and assisted 
with continuity of care. 
“It was very useful and enriching for my role to be 
able to speak to them and I could hear the nerves 
in their voice sometimes and just to say, you know, 
you’re not alone through the process”. (Health Care 
Professional 1) 
Subtheme 3.2: Education Seven (53.8%) patients dis-
cussed some engagement with the lifestyle education 
component of Active+me. Patients who used the infor-
mation found it helpful, although potentially overwhelm-
ing in quantity. 
“…when you go through an experience like I did you 
are bombarded with information from many dif-
ferent angles, and a lot of it obviously is repeated, 
which is good because it means it gets in there, but 
you are, bombarded”. (Male, 54) 
Healthcare professionals said further development of 
the lifestyle education component would enhance this 
aspect of the programme, and help patients self-manage 
their condition, in the longer-term. 
“I think from the education point of view… if we 
were to fully engage and develop it, it’s a really good 
resource that patients can have available for them 
to have whenever they need it to look through in the 
long term”. (Health Care Professional 2) 
Discussion 
In 2020, restrictions on face-to-face contact, due to 
COVID-19, led to a rapid increase in the use of tech-
nology to deliver CR [3]. Some technologies, includ-
ing Active+me, had not been evaluated in patients with 
heart disease. We are the frst to evaluate Active+me in 
a cohort of patients participating in a Phase III CR pro-
gramme during the COVID-19 pandemic. Interviews 
showed that patients engaged with Active+me and that 
they were more confdent at managing their own health 
after completing the programme. Tis was refected by an 
increased in PAM score, our primary outcome measure, 
after participating in CR with Active+me. Interestingly, 
PAM increased most in patients at high risk of exercise-
induced cardiovascular events. Changes in PAM scores 
were accompanied by reductions in systolic blood pres-
sure, waist circumference, and increased self-reported 
physical activity. However, several patients reported 
lower PAM scores after the intervention which may 
indicate a need to refne the content provided to some 
patients. We were unable to draw any conclusions on 




















whether participation in CR with Active+me improved 
psychosocial health due to the low number of question-
naire responses (Appendix 2). 
Patient activation 
One aim of CR is to help patients learn how to self-
manage their heart condition [6]. We found that PAM 
scores, a metric that quantifes the skill, confdence and 
knowledge a patient has to manage their health [7],
increased after CR with Active+me (from 65.5 to 70.2). 
Tis is consistent with previous data showing that PAM 
scores increased by 4.2 points after hospital-based CR, 
and 4.8 points after telemetry-based CR [22]. Te overall 
change in PAM score in our study appeared to be driven 
by increases among high risk patients (61.9 to 75.0). No 
adverse events were reported. Tese fndings provide 
reassurances about the safety and beneft of remotely 
delivered CR for patients, including high risk patients, 
and should help reverse the trend of digital exclusion for 
this group of patients [3].
Te reason for greater improvements in PAM scores 
among high risk patients, but not low and moderate risk 
patients, is unclear. Lower baseline PAM scores in high 
risk patients might have suggested greater potential to 
increase PAM scores. However, baseline PAM scores 
were similar in all risk groups (Table  2). Tus, changes 
in PAM score appear to be independent of baseline PAM 
scores, between risk groups, in this instance.
In qualitative interviews, patients with larger increases 
in PAM scores generally discussed more meaningful 
health benefts following CR with Active+me. Terefore 
Active+me, seems to be more benefcial for high risk 
patients. Tese patients may be more motivated to learn 
about how to manage their health, compared to moder-
ate and low risk individuals. Tis may be because they are 
more aware of their poor health and are more motivated 
to see an improvement in their health. However, this is 
speculative. 
Cardiovascular risk factors 
Blood pressure in our cohort of patients was well man-
aged from the outset. However, cardiovascular risk asso-
ciated with hypertension exists on a continuum [28].
Te risk of cardiovascular events is halved with each 
20mmHg reduction in systolic blood pressure, down to 
~115mmHg [28]. Te reduction in systolic blood pres-
sure, from 125mmHg to 119mmHg, is consistent with 
changes following comprehensive CR (−3.2mmHg; 95% 
CI −5.6 to −0.8) [29]. Importantly, the −3.2mmHg 
reduction in systolic blood pressure may contrib-
ute towards the 37% reduction in all-cause mortality 
observed in patients participating in comprehensive CR 
[29]. Te systolic blood pressure reduction of ~6mmHg 
following participation in CR with Active+me may there-
fore be meaningful.
Te reasons for the reduction in systolic blood pressure 
are likely to be multifactorial. For example, Active+me 
provides support to encourage medication adherence. 
Terefore, better adherence to anti-hypertensive medi-
cation may have contributed to a reduction in systolic 
blood pressure. However, this was not measured in this 
study. Patients using Active+me also reported a reduc-
tion in waist circumference, a surrogate of abdominal 
obesity. Weight loss >5% is associated with a reduction 
in systolic blood pressure [30]. However, unlike waist cir-
cumference, BMI was unchanged after Active+me. Tis 
discrepancy may be due to patients measuring their own 
waist circumference. Waist measurements may therefore 
be inaccurate. It may also be due to incomplete data for 
waist circumference measurements (Appendix 2). Nota-
bly, carrying the last observation forward resulted in a 
smaller reduction in waist circumference measurements 
than with the raw analysis. An alternative explanation 
for the reduction in blood pressure could be the increase 
self-reported physical activity levels. Increased participa-
tion in physical activity levels is associated with a reduc-
tion in systolic blood pressure [31]. However, changes 
in self-reported physical activity were not refected in 
accelerometer-derived measurements of physical activ-
ity. Tis may be because the physical activity tracker did 
not measure exercise intensity and/or because it only 
detected steps. Activities such as cycling may not have 
been recorded. Self-reported physical activity may have 
increased because this measure captured activities that 
were not recorded by the activity tracker and/or because 
it captured changes in intensity of physical activity. Inter-
views also suggested that some patients did not use the 
physical activity tracker which could have resulted in 
missing data. 
Active+me adherence 
In 2019, the UK’s National Audit for Cardiac Reha-
bilitation (NACR) reported that 50% of eligible patients 
chose to participate in CR. Of these, 77% completed 
their CR programme [32]. Whilst only ~30% of patients 
referred for CR used Active+me, completion of CR with 
Active+me was 93.4%. Tese data suggest that Active+me 
could help increase completion rates of CR and therefore 
maximise the beneft of CR to the patient. Te high pro-
gramme completion rates also indicate that patients are 
more likely to complete a CR programme if they chose 
the mode of delivery. However, qualitative interviews 
showed that some patients disengaged with certain ele-
ments of Active+me. More research and intervention 



















   
 
  
    
  
  
         
              
 
development is needed to improve patient fdelity to the 
diferent components of Active+me. 
Limitations and conclusion 
Active+me with routine CR is acceptable to patients and 
healthcare professionals. Overall, fndings support that 
patients have better skills, knowledge, and confdence to 
manage their heart condition after completing CR with 
Active+me. Patients at high risk of cardiovascular events 
seemed to beneft the most. Improvements in patient 
activation were associated with lower systolic blood pres-
sure, and increased self-reported physical activity levels, 
in the short-term. Tus, current evidence supports the 
use of Active+me for patients in CR. However, as this was 
a cohort evaluation of newly adopted standard practice, 
some secondary outcome measures collected as part of 
routine care were incomplete. Tese included waist cir-
cumference measurements and psychosocial question-
naires (Appendix 2). Te low number of responses could 
explain why no improvements in psychosocial measure-
ments were reported. Further, the number of participants 
in sub-groups was small and unevenly distributed. Con-
clusions regarding these outcome measures should there-
fore be interpreted with caution. Additionally, we did not 
collect control data, and data were only collected from 
one site. Te generalisability of our fndings are therefore 
unclear. Finally, although we obtained qualitative data 
about whether patients engaged with Active+me, we did 
not collect quantitative data on app usage or treatment 
fdelity. Further large-scale controlled studies are needed 
to confrm the beneft of using Active+me to support 
remotely delivered CR. 
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